Goserelin Dosage

Medically reviewed by Drugs.com. Last updated on Dec 11, 2024.

Usual Adult Dose for Prostate Cancer

For the palliative treatment of advanced carcinoma of the prostate:
3.6 mg or 10.8 mg subcutaneously into the upper abdominal wall once
The 3.6 mg dosage may be repeated every 28 days.
The 10.8 mg dosage may be repeated every 12 weeks.
Intended for long-term administration unless clinically inappropriate.

Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males: SubQ:
Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant
OR
28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy)

Uses:

• In combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should start 8 weeks prior to radiation therapy and continue during radiation.
• For palliative treatment of advanced carcinoma of the prostate.

Usual Adult Dose for Endometriosis

3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days

The recommended duration of therapy is 6 months.

Use: For the management of endometriosis, including pain relief and reduction of endometriotic lesions.

Usual Adult Dose for Breast Cancer-Palliative

For use in the palliative treatment of advanced breast cancer: 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days

Intended for long-term administration unless clinically inappropriate.

Use: For the palliative treatment of advanced breast cancer in pre- and perimenopausal women

Usual Adult Dose for Bleeding

1 or 2 of the 3.6 mg subcutaneous depot injections (with each depot given 4 weeks apart). When 1 depot is administered, surgery should be performed at 4 weeks. When 2 depots are administered, surgery should be performed within 2 to 4 weeks following administration of the second depot.

Use: For use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Pregnancy

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Caution should be taken while inserting the implant into the interior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches
• Caution should be taken when administering this drug to patients with a low BMI and/or who are receiving full anticoagulation medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer